Heterozygous individuals for ERCC2 Asp312Asn which received a hormonal replacement therapy (HRT) exhibited a risk to develop breast cancer (OR = 1.39; 95% CI = 0.97–1.99). The gene discussed is ERCC2; the disease is breast carcinoma.